Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes
- Predictive Value of Postprandial Glucose for CV Events in Type 2 Diabetes. // Neurology Alert;Dec2011 Clinical Briefs in Primary, p23
The article discusses research by F. Cavalot et al published in a 2011 issue of "Diabetes Care" on the role of posprandial glucose in predicting cardiovascular events and mortality in type 2 diabetes.
- Intensive glucose control increased mortality and did not prevent cardiovascular events in type 2 diabetes. Byington, R. P. // Evidence Based Medicine;Dec2008, Vol. 13 Issue 6, p169
Design: randomised controlled trial (Action to Control Cardiovascular Risk in Diabetes [ACCORD]). Allocation concealment: concealed. Blinding: blinded (outcome adjudication committee and laboratory staff). Setting: 77 centres in the USA and Canada. Patients: 10 251 patients 40-79 years of age...
- Older Adults With Diabetes, Low Glucose at Higher Risk. // Today's Dietitian;Jun2011, Vol. 13 Issue 6, p50
No abstract available.
- Aggressive Glycemic Control Might Not Be Best Choice for All Diabetic Patients. Mitka, Mike // JAMA: Journal of the American Medical Association;3/24/2010, Vol. 303 Issue 12, p1137
The article discusses studies on glycemic control as the primary goal of diabetes management. One study, published in the "Lancet," discovered that high and low hemoglobin (HbA1C) levels were linked to increased all-cause mortality and cardiac events in patients with type 2 diabetes. Another...
- Relationship of Glycated Hemoglobin Levels with Myocardial Injury following Elective Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus. Li, Xiao-Lin; Li, Jian-Jun; Guo, Yuan-Lin; Zhu, Cheng-Gang; Xu, Rui-Xia; Li, Sha; Qing, Ping; Wu, Na-Qiong; Jiang, Li-Xin; Xu, Bo; Gao, Run-Lin // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1
Background: Glycated hemoglobin (HbA1c) predicts clinical cardiovascular disease or cardiovascular mortality. However, the relationship between HbA1c and myocardial injury following elective percutaneous coronary intervention (PCI) in patients with type 2 diabetes mellitus (DM) has not been...
- Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes. PAI-FENG HSU; SHIH-HSIEN SUNG; HAO-MIN CHENG; JONG-SHIUAN YEH; WEN-LING LIU; WAN-LEONG CHAN; CHEN-HUAN CHEN; PESUS CHOU; SHAO-YUAN CHUANG // Diabetes Care;Apr20123, Vol. 36 Issue 4, p894
OBJECTIVE--Hypoglycemia is associated with serious health outcomes for patients treated for diabetes. However, the outcome of outpatients with type 2 diabetes who have experienced hypoglycemia episodes is largely unknown. RESEARCH DESIGN AND METHODS--The study population, derived from the...
- Glycated Hemoglobin and All-Cause and Cause-Specific Mortality in Singaporean Chinese Without Diagnosed Diabetes: The Singapore Chinese Health Study. Bancks, Michael P.; Odegaard, Andrew O.; Pankow, James S.; Woon-Puay Koh; Jian-Min Yuan; Gross, Myron D.; Pereira, Mark A. // Diabetes Care;Dec2014, Vol. 37 Issue 12, p3180
OBJECTIVE Glycated hemoglobin (HbA1c) is a robust biomarker of the preceding 2 to 3 months average blood glucose level. The aim of this study was to examine the association between HbA1c and mortality in a cohort of Southeast Asians. RESEARCH DESIGN AND METHODS Analysis of 7,388 men and women,...
- Prognostic importance of baseline and serial glycated hemoglobin levels in high-risk patients with type 2 diabetes: the Rio de Janeiro Type 2 Diabetes Cohort Study. Cardoso, Claudia; Leite, Nathalie; Ferreira, Marcel; Salles, Gil // Acta Diabetologica;Feb2015, Vol. 52 Issue 1, p21
The prognostic importance of baseline and serial glycated hemoglobin (HbA) changes for cardiovascular outcomes is still debated. We aimed to evaluate it in 620 high-risk individuals with type 2 diabetes (mean age 60.4 years, 37 % males, 55 % Caucasians). Patients had HbA levels measured at study...
- No mortality benefit in reducing HbA1c below 9%. // Pulse;3/10/2010, Vol. 70 Issue 8, p9
The article presents a study conducted by Dutch researchers which found out that the reduction of HbA1c levels to below 9% does not lower mortality rates in patients with type 2 diabetes.